Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center

被引:0
|
作者
Botella, Carmen [1 ]
Galian, Jose Antonio [1 ]
Jimenez-Coll, Victor [1 ]
Fernandez-Gonzalez, Marina [1 ]
Morales, Francisco [2 ]
Martinez-Gomez, Gloria [3 ]
Gonzalez-Lopez, Rosana [1 ]
Alegria, Maria Jose [1 ]
Moya, Maria Rosa [1 ]
Martinez-Banaclocha, Helios [1 ]
Minguela, Alfredo [1 ]
Legaz, Isabel [4 ]
Llorente, Santiago [2 ]
Muro, Manuel [1 ]
机构
[1] Univ Clin Hosp Virgen Arrixaca, Biomed Res Inst Murcia IMIB, Immunol Serv, Murcia 30120, Spain
[2] Univ Clin Hosp Virgen Arrixaca, Biomed Res Inst Murcia IMIB, Nephrol Serv, Murcia 30120, Spain
[3] Univ Clin Hosp Virgen Arrixaca, Biomed Res Inst Murcia IMIB, Urol Serv, Murcia 30120, Spain
[4] Univ Murcia, Biomed Res Inst Murcia IMIB, Fac Med, Dept Legal & Forens Med,Reg Campus Int Excellence, Murcia 30100, Spain
来源
LIFE-BASEL | 2024年 / 14卷 / 11期
关键词
donor-derived circulating free DNA (dd-cfDNA); kidney transplant; graft rejection; biomarker; non-rejection (NR); antibody-mediated rejection (ABMR); borderline rejection (BR); T-cell-mediated rejection (TCMR); TRANSPLANTATION; REJECTION;
D O I
10.3390/life14111491
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
(1) Background: donor-derived circulating free DNA (dd-cfDNA), an innovative biomarker with great potential for the early identification and prevention of graft damage. (2) Methods: Samples were collected prospectively and the study was performed retrospectively to analyze dd-cfDNA plasma levels in 30 kidney transplant patients during their post-transplant follow-up (15 days, 3, 6, and 9 months), to determine if the result could be of interest in the identification of possible adverse events, especially rejection. The aim was to verify whether the data on sensitivity, specificity, NPV, and PPV compare with reference values and creatinine values. (3) Results: We observed levels of dd cfDNA > 1% in six of nine patients with active rejection (ABMR or TCMR) and elevated values (>0.5%) in two other patients in this rejection group. Our results show low values of sensitivity = 50%, specificity = 61.11%, rejection NPV = 64.71%, and rejection PPV = 46.13% of the technique compared to reference values previously published. With respect to creatinine, only for TCRM, we observed better results for dd-cfDNA in these parameters than in creatinine. Also, our data suggest that dd-cfDNA could help to differentiate those patients with dnDSAs that are going to through rejection better than creatinine, specially at 15 d post transplant. In this study, this appears to have no positive predictive value for borderline rejection (BR) or TCMR IA. (4) Conclusions: plasma levels of dd-cfDNA could be considered an additional or alternative biomarker for graft rejection monitoring in early post-kidney transplant up to several months before its clinical presentation, especially for patients with suspected TCMR or ABMR.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Protocol-based donor-derived cell-free DNA surveillance in kidney transplant recipients: A single-center experience
    Nissaisorakarn, Pitchaphon
    Patel, Het
    Amtul, Aala
    Pavlakis, Martha
    CLINICAL NEPHROLOGY, 2022, 98 (02) : 65 - 74
  • [2] The Current State of Donor-Derived Cell-Free DNA Use in Allograft Monitoring in Kidney Transplantation
    Kueht, Michael L.
    Dongur, Laxmi Priya
    Cusick, Matthew
    Stevenson, Heather L.
    Mujtaba, Muhammad
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (10):
  • [3] Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients
    Huang, Edmund
    Sethi, Supreet
    Peng, Alice
    Najjar, Reiad
    Mirocha, James
    Haas, Mark
    Vo, Ashley
    Jordan, Stanley C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (06) : 1663 - 1670
  • [4] Donor-derived Cell-free DNA in Infections in Kidney Transplant Recipients: Case Series
    Goussous, Naeem
    Xie, Wen
    Dawany, Noor
    Scalea, Joseph R.
    Bartosic, Amanda
    Haririan, Abdolreza
    Kalil, Roberto
    Drachenberg, Cinthia
    Costa, Nadiesda
    Weir, Matthew R.
    Bromberg, Jonathan S.
    TRANSPLANTATION DIRECT, 2020, 6 (07): : E568
  • [5] Racial Variation of Donor-Derived Cell-Free DNA in Kidney Transplant Recipients
    Ralph, Oliver G.
    Williams, Michael D.
    Chan, Edie Y.
    Olaitan, Oyedolamu
    PROGRESS IN TRANSPLANTATION, 2025, 35 (01) : 14 - 21
  • [6] Causes of Renal Allograft Injury in Recipients With Normal Donor-derived Cell-free DNA
    Xie, Wen Yan
    Kim, Kevin
    Goussous, Naeem
    Drachenberg, Cinthia B.
    Scalea, Joseph R.
    Weir, Matthew R.
    Bromberg, Jonathan S.
    TRANSPLANTATION DIRECT, 2021, 7 (04): : E679
  • [7] Utilization of donor-derived Cell-Free DNA in pediatric kidney transplant recipients: A single center study
    Ranch, Daniel
    Fei, Mingwei
    Kincade, Elisabeth
    Piburn, Kim
    Hitchman, Kelley
    Klein, Kelsey
    PEDIATRIC TRANSPLANTATION, 2024, 28 (01)
  • [8] Perspectives on Donor-Derived Cell-Free DNA in Kidney Transplant Recipients with Systemic Lupus Erythematosus
    Williams, Michael D.
    Gupta, Vineet
    Chan, Edie Y.
    Olaitan, Oyedolamu
    PROGRESS IN TRANSPLANTATION, 2023, 33 (02) : 182 - 183
  • [9] The clinical value of donor-derived cell-free DNA measurements in kidney transplantation
    Garg, Neetika
    Mandelbrot, Didier A.
    Parajuli, Sandesh
    Aziz, Fahad
    Astor, Brad C.
    Chandraker, Anil
    Djamali, Arjang
    TRANSPLANTATION REVIEWS, 2021, 35 (04)
  • [10] Kidney Allograft Monitoring by Combining Donor-Derived Cell-Free DNA and Molecular Gene Expression: A Clinical Management Perspective
    Rizvi, Asim
    Faiz, Sara
    Thakkar, Parin H.
    Hussain, Syed
    Gamilla-Crudo, Ann N.
    Kueht, Michael
    Mujtaba, Muhammad A.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (08):